
### [MONDO:0018918](http://purl.obolibrary.org/obo/MONDO_0018918)
**Label:** carcinoma of gallbladder and extrahepatic biliary tract

**Subclasses:** [MONDO:0019087](http://purl.obolibrary.org/obo/MONDO_0019087) (cholangiocarcinoma), 

**Corr. equiv. classes:** [Orphanet:70567](http://www.orpha.net/ORDO/Orphanet_70567), [OMIM:615619](http://purl.obolibrary.org/obo/OMIM_615619), 

**Class expressions from DL-Learner:**

- [HP:0100574](http://purl.obolibrary.org/obo/HP_0100574) (Biliary tract neoplasm) 81.62%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100871](http://purl.obolibrary.org/obo/HP_0100871) (Abnormality of the palm))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100869](http://purl.obolibrary.org/obo/HP_0100869) (Palmar telangiectasia))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100831](http://purl.obolibrary.org/obo/HP_0100831) (Abnormality of vitamin K metabolism))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100763](http://purl.obolibrary.org/obo/HP_0100763) (Abnormality of the lymphatic system))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100651](http://purl.obolibrary.org/obo/HP_0100651) (Type I diabetes mellitus))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100626](http://purl.obolibrary.org/obo/HP_0100626) (Chronic hepatic failure))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100585](http://purl.obolibrary.org/obo/HP_0100585) (Telangiectasia of the skin))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100575](http://purl.obolibrary.org/obo/HP_0100575) (Neoplasm of the gallbladder))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100514](http://purl.obolibrary.org/obo/HP_0100514) (Abnormality of vitamin E metabolism))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100513](http://purl.obolibrary.org/obo/HP_0100513) (Vitamin E deficiency))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100512](http://purl.obolibrary.org/obo/HP_0100512) (Vitamin D deficiency))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100511](http://purl.obolibrary.org/obo/HP_0100511) (Abnormality of vitamin D metabolism))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100508](http://purl.obolibrary.org/obo/HP_0100508) (Abnormality of vitamin metabolism))) 75.00%
- [HP:0030153](http://purl.obolibrary.org/obo/HP_0030153) (Cholangiocarcinoma) and (not ([HP:0100326](http://purl.obolibrary.org/obo/HP_0100326) (Immunologic hypersensitivity))) 75.00%


